Silexion Therapeutics Ltd.
Silexion Therapeutics Ltd. (SLXNW) Company Profile & Overview
Explore Silexion Therapeutics Ltd.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Silexion Therapeutics Ltd. (SLXNW) Company Profile & Overview
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.